XGN
Exagen Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$7.58
+0.53%Aug 4, 2026, 12:00 UTC
Exagen Inc. reported its financial results for the quarter ended June 30, 2026, achieving record total revenue, test volume, and trailing twelve-month ASP, reducing net loss by nearly 30%, and narrowing adjusted EBITDA loss to $0.1 million.